Doug Janzen


Doug Janzen brings over 20 years of experience in life sciences to Synaptive’s Board of Directors with leadership experience in corporate finance, business development, and management. During his nine-year tenure at Cardiome Pharma (NASDAQ: CRME), Doug held a series of positions including chief financial officer (2003 to 2005), president and chief business officer (2005 to 2009), and president and CEO (2009 to 2012). During this time, he raised over C$300 million from investors, completed over C$1 billion in licensing deals, and led a partnership with Merck to bring Cardiome’s lead product, Brinavess, through to clinical approval and marketing in Europe. Doug is currently co-founder and managing director of NorthView Ventures, chairman and CEO of Aequus Pharmaceuticals, and serves on the Boards of Aequus Pharmaceuticals, Alabaster Technologies, Abcellera (chairman), Ico Therapeutics, Perimeter Medical Imaging, and Renaissance Biosciences. Prior to Cardiome, Doug was an investment banker with Cormark Securities, acting as managing director of life sciences, and has completed over C$1 billion in equity financing for Canadian biotech companies. Doug is past chair of LifeSciences BC, has served as a director with Biotech Canada and is a past winner of Business in Vancouver’s “Top 40 Under 40 Award.”

© Synaptive Medical, 2012-2019. All rights reserved.

Use of this webpage is subject to our terms of use and privacy policy. Images and video are for demonstrative purposes only. SYNAPTIVE, the Synaptive logo, BrightMatter, and Bridge are trademarks of Synaptive Medical Inc., or its subsidiaries. Patents Pending. Please contact Synaptive Medical for information on regulatory clearance status of our products in your jurisdiction.

Close Menu